Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Rolling Forward with Cannabis Production Facility

  • Facility in Costa Mesa, California, will enable full range of cannabis distribution services
  • Powdered cannabis CBD and THC formulations for beverage alternatives expected to drive multi-billion-dollar market
  • Pivot Pharmaceuticals expects to have licensing to begin manufacturing by July, with equipment installed by August

Cannabis-friendly biopharmaceutical firm Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is rolling at a good pace with its recent announcement that its Canada-based operation has also found solid footing in the United States through a lease agreement on a California manufacturing facility that will allow the company to operate wholesale medical marijuana distribution, manufacture, processing and transportation and set up research and development laboratories.

According to a May news release (, Pivot intends to use the manufacturing facility to begin production of a portfolio of patented cannabis-derivatives that will be marketed under the “Pivot Naturals” brand. The company will use high-quality cannabis oil and plant elements to generate food additive powders and capsules through its patented “Ready To Infuse Cannabis (RTIC)” process for sale in the California market — the largest marijuana market on the planet.

Once it has obtained the licensing, the Costa Mesa production pipeline will look to take advantage of annual legal cannabis sales in California that totaled about $2.8 billion in 2016 and are expected to grow to $3.7 billion this year, then $5.1 billion next year, thanks in large part to the state’s legalization of adult recreational use in January (

“I expect that we will receive the necessary local and state manufacturing licenses in July 2018 and complete production equipment installation by August 2018. Pivot Naturals’ capsules, stick packs and bulk powder should be on the shelves of dispensaries in California by Q4 2018,” Patrick J. Rolfes, president of Pivot Naturals, LLC, stated in the news release. “In addition, we have been inundated by requests to supply our patented RTIC powder for white label products and we fully intend to continue to sign manufacturing and supply agreements with respected cannabis brands in our state.”

Pivot’s RTIC process and Solmic Micelle water-soluble technologies will be used to generate a dry cannabis powder that can be used as a baking additive, in pet products and in a variety of retail items. Part of the manufacturing facility will be used to produce topical creams and oral drug delivery technologies, but, at the moment, one of the company’s key focuses is the potential to stir a bit of flavorless, odorless cannabis powder into a favorite beverage — either as non-psychotropic CBD formulations or more intoxicating THC formulations.

“The beverage market opportunity is just too big to ignore and our patented technologies lend themselves well to this space,” Pivot CEO Patrick Frankham stated in a May news release ( “Existing solutions are unable to provide consistent dosing nor offer the most effective bioavailability, of which our patented technology is able to remedy. … It is our intention to supply CBD and THC additives as ingredients for global wine, spirits, beer and energy drink companies who have the capabilities for large scale manufacturing and distribution.”

Equity research firm Cowen and Co. predicts that the cannabis market will generate $75 billion in annual sales by 2030 (, based in large part on its analysis of consumers’ “social lubricant” binge drinking behavior and the drive to substitute cannabis for alcohol in some beverages.

“We found that legal cannabis states (as of 2016) binge drink 13% fewer times per month than non-cannabis states,” the company’s report states.

For more information, visit the company’s website at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Pivot Pharmaceuticals Inc. PVOTF. Bookmark the permalink.

Comments are closed.